[go: up one dir, main page]

DE602007009230D1 - Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors - Google Patents

Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors

Info

Publication number
DE602007009230D1
DE602007009230D1 DE602007009230T DE602007009230T DE602007009230D1 DE 602007009230 D1 DE602007009230 D1 DE 602007009230D1 DE 602007009230 T DE602007009230 T DE 602007009230T DE 602007009230 T DE602007009230 T DE 602007009230T DE 602007009230 D1 DE602007009230 D1 DE 602007009230D1
Authority
DE
Germany
Prior art keywords
interleukin
controlled release
converting enzyme
enzyme inhibitor
oral formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009230T
Other languages
English (en)
Inventor
Irina Nikolaevna Kadiyala
Wu Lin
Patricia Hurter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE602007009230D1 publication Critical patent/DE602007009230D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602007009230T 2006-05-31 2007-05-30 Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors Active DE602007009230D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80977906P 2006-05-31 2006-05-31
PCT/US2007/012715 WO2007142951A2 (en) 2006-05-31 2007-05-30 Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor

Publications (1)

Publication Number Publication Date
DE602007009230D1 true DE602007009230D1 (de) 2010-10-28

Family

ID=38802004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009230T Active DE602007009230D1 (de) 2006-05-31 2007-05-30 Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors

Country Status (19)

Country Link
US (2) US20080070972A1 (de)
EP (1) EP2037887B1 (de)
JP (1) JP2009538912A (de)
KR (1) KR20090018843A (de)
CN (1) CN101489530A (de)
AT (1) ATE481089T1 (de)
AU (1) AU2007254990A1 (de)
CA (1) CA2653625A1 (de)
CY (1) CY1111439T1 (de)
DE (1) DE602007009230D1 (de)
DK (1) DK2037887T3 (de)
ES (1) ES2351947T3 (de)
IL (1) IL195572A (de)
MX (1) MX2008015253A (de)
PL (1) PL2037887T3 (de)
PT (1) PT2037887E (de)
RU (1) RU2446800C2 (de)
SI (1) SI2037887T1 (de)
WO (1) WO2007142951A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
EP2256113A1 (de) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Serinprotease-Hemmer
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CN101489557B (zh) 2006-02-27 2013-12-18 弗特克斯药品有限公司 包含vx-950的共晶体和包含所述共晶体的药物组合物
KR20080112303A (ko) * 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
WO2008106151A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2704284A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN111346060A (zh) * 2020-03-23 2020-06-30 山东达因海洋生物制药股份有限公司 一种释药速度可控的乙基纤维素掩味微球及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
JPS6242918A (ja) * 1985-08-20 1987-02-24 Kaken Pharmaceut Co Ltd 持続性製剤
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
US4777050A (en) * 1987-03-23 1988-10-11 Schering Corporation Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CN102362867A (zh) * 2004-05-15 2012-02-29 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作

Also Published As

Publication number Publication date
CY1111439T1 (el) 2015-08-05
ATE481089T1 (de) 2010-10-15
CN101489530A (zh) 2009-07-22
DK2037887T3 (da) 2011-01-03
SI2037887T1 (sl) 2011-01-31
RU2446800C2 (ru) 2012-04-10
WO2007142951A2 (en) 2007-12-13
PL2037887T3 (pl) 2011-03-31
MX2008015253A (es) 2008-12-17
CA2653625A1 (en) 2007-12-13
US20080070972A1 (en) 2008-03-20
JP2009538912A (ja) 2009-11-12
EP2037887B1 (de) 2010-09-15
PT2037887E (pt) 2010-12-07
KR20090018843A (ko) 2009-02-23
WO2007142951A3 (en) 2008-03-06
AU2007254990A1 (en) 2007-12-13
EP2037887A2 (de) 2009-03-25
IL195572A0 (en) 2009-09-01
IL195572A (en) 2012-08-30
RU2008152085A (ru) 2010-07-10
US20110021598A1 (en) 2011-01-27
ES2351947T3 (es) 2011-02-14

Similar Documents

Publication Publication Date Title
DE602007009230D1 (de) Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors
DOP2009000257A (es) Inhibidores de cinasa p70 s6
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
EP2592073A3 (de) Humane Proteintyrosinphosphathemmer und ihre Verwendung
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
EP2592072A3 (de) Humane Proteintyrosinphosphathemmer und ihre Verwendung
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
AR071809A1 (es) Composiciones orales y sus usos
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
DK2695609T3 (da) Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
UA100190C2 (en) Akt and p70 s6 kinase inhibitors
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
GT200600117A (es) Nuevos compuestos farmaceuticos
EP2044926A4 (de) Orale zusammensetzung für dentale zwecke
DK3348258T3 (da) Orale og injicerbare formuleringer af tetracyclinforbindelser
CL2008001810A1 (es) Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades.
DK1608344T3 (da) Orale cladribin-formuleringer
MY162054A (en) Inhibitor of attachment of periodontal disease-inducing bacterium onto surfaces of teeth, oral biofilm formation inhibitor, and composition for oral applications
DE502007005946D1 (de) Auto-adhäsiver klebstoff
GT200600123A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion